Apsara establishes global patent portfolio for aquaporin-4 antibodies
Client(s) Apsara Therapeutics, Inc.
Jones Day represents Apsara Therapeutics, Inc. in the establishment of a global patent portfolio relating to aquaporin-4 (AQP4) antibodies for the treatment of neuromyelitis optica.